TAC/MTX vs. TAC/MMF/PTCY for Prevention of Graft-versus-Host Disease and Microbiome and Immune Reconstitution Study (BMT CTN 1703/1801)

Sponsor
Medical College of Wisconsin (Other)
Overall Status
Active, not recruiting
CT.gov ID
NCT03959241
Collaborator
National Heart, Lung, and Blood Institute (NHLBI) (NIH), Blood and Marrow Transplant Clinical Trials Network (Other), National Cancer Institute (NCI) (NIH), National Marrow Donor Program (Other)
428
Enrollment
39
Locations
2
Arms
55.3
Anticipated Duration (Months)
11
Patients Per Site
0.2
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

1703: The study is designed as a randomized, phase III, multicenter trial comparing two acute graft-versus-host disease (aGVHD) prophylaxis regimens: tacrolimus/methotrexate (Tac/MTX) versus post-transplant cyclophosphamide/tacrolimus/mycophenolate mofetil (PTCy/Tac/MMF) in the setting of reduced intensity conditioning (RIC) allogeneic peripheral blood stem cell (PBSC) transplantation.

1801: The goal of this protocol is to test the primary hypothesis that the engraftment stool microbiome diversity predicts one-year non-relapse mortality in patients undergoing reduced intensity allogeneic HCT.

Condition or DiseaseIntervention/TreatmentPhase
Phase 3

Detailed Description

1703: Graft-versus-Host Disease (GVHD) is a complication that affects many hematopoietic stem cell transplant (HSCT) patients; it occurs when the new cells from a transplant attack the recipient's body. The current standard GVHD prophylaxis regimen for patients with hematologic malignancies undergoing HSCT involves a combination of immunosuppressive agents given for the first 6 months after transplant.

The standard strategy of Tacrolimus/Methotrexate will be used as a control arm in comparison to one other treatment plan utilizing Tacrolimus/Mycophenolate Mofetil/Post-Transplant Cyclophosphamide. Study participants will receive an infusion of mobilized peripheral blood stem cell grafts on both arms. Study participants will be randomized to one of these two treatment arms.

1801: A relationship between the intestinal microbiota and graft-versus-host disease (GVHD) has long been appreciated but is still not well understood. Mice transplanted in germ-free conditions or treated with gut-decontaminating antibiotics developed less severe GVHD. Clinical studies initially suggested a benefit from near-total bacterial decontamination, but later showed no clear benefit and this approach was discontinued in the early 1990s. Partial gut decontamination continues to be practiced at many centers. More recently, the advent of next-generation sequencing (NGS) has resulted in cheaper and easier characterization of complex microbial mixtures. This has led to a renewed interest in evaluating the relationship between the microbiota and human health and disease, including recipients of hematopoietic cell transplantation (HCT). Similarly, NGS has also contributed to significant advancements in the investigator's understanding of immune reconstitution in HCT patients and how this may impact clinica outcomes.

The goal of this protocol is to test the primary hypothesis that the engraftment stool microbiome diversity predicts one-year non-relapse mortality in patients undergoing reduced intensity allogeneic HCT.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
428 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Patients will be randomized at a ratio of 1:1 between the treatment arms using permuted blocks of random sizes.Patients will be randomized at a ratio of 1:1 between the treatment arms using permuted blocks of random sizes.
Masking:
None (Open Label)
Primary Purpose:
Prevention
Official Title:
A Randomized, Multicenter, Phase III Trial of Tacrolimus/Methotrexate Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 1703; Progress III); Companion Study: Microbiome and Immune Reconstitution in Cellular Therapies and Hematopoietic Stem Cell Transplantation (BMT CTN 1801; Mi-Immune)
Actual Study Start Date :
Jun 25, 2019
Anticipated Primary Completion Date :
Feb 1, 2023
Anticipated Study Completion Date :
Feb 1, 2024

Arms and Interventions

ArmIntervention/Treatment
Active Comparator: Tacrolimus/Methotrexate

Mobilized Peripheral Blood Stem Cell graft with Tacrolimus/Methotrexate

Procedure: Mobilized Peripheral Blood Stem Cell graft with Tacrolimus/Methotrexate
Mobilized PBSC grafts will be administered on Day 0 to all patients according to individual institutional guidelines after appropriate processing and quantification has been performed by the local laboratory. Stem cells are administered through an indwelling central venous catheter. If infusion occurs over two days, Day 0 is the first day the infusion is initiated.
Other Names:
  • HSCT
  • Drug: Tacrolimus
    Tacrolimus will be given per institutional practices, orally at a dose of 0.05-0.06 mg/kg/day or intravenously at a dose of 0.02-0.03 mg/kg/day starting on Day -3. The dose of tacrolimus may be rounded to the nearest 0.5 mg for oral formulations. Subsequent dosing will be based on blood levels per institutional guidelines with a suggested range of 5-15. If patients are on medications which alter the metabolism of tacrolimus (e.g.concurrent CYP3A4 inhibitors), the initial starting dose and subsequent doses should be altered as per institutional practices. Tacrolimus taper can be initiated at a minimum of 90 days post HCT if there is no evidence of active GVHD. The rate of tapering will be done according institutional practices and patients should be off tacrolimus by Day 180 post HCT if there is no evidence of active GVHD.
    Other Names:
  • Prograf®
  • FK506
  • Drug: Methotrexate
    Methotrexate will be administered at the doses of 15 mg/m2 IV bolus on Day +1, and 10 mg/m2 IV bolus on Days +3, +6 and +11 after hematopoietic stem cell infusion. Methotrexate should be dose reduced, given with leucovorin rescue, or held for complications such as severe mucositis per institutional guidelines.
    Other Names:
  • MTX
  • Experimental: Tacrolimus/MMF/PTCY

    Mobilized Peripheral Blood Stem Cell graft with Tacrolimus/Mycophenolate Mofetil/Post-Transplant Cyclophosphamide

    Procedure: Mobilized Peripheral Blood Stem Cell graft with Tacrolimus/Mycophenolate Mofetil/Post-Transplant Cyclophosphamide
    Mobilized PBSC grafts will be administered on Day 0 to all patients according to individual institutional guidelines after appropriate processing and quantification has been performed by the local laboratory. Stem cells are administered through an indwelling central venous catheter. If infusion occurs over two days, Day 0 is the first day the infusion is initiated.
    Other Names:
  • HSCT
  • Drug: Tacrolimus
    Tacrolimus will be given per institutional practices, orally at a dose of 0.05-0.06 mg/kg/day or intravenously at a dose of 0.02-0.03 mg/kg/day starting Day +5. Starting tacrolimus dose can be modified to account for possible drug interactions (e.g. concurrent CYP3A4 inhibitor use) according to institutional guides. Serum levels of tacrolimus will be measured at Day +7 and then should be checked weekly thereafter, and the dose adjusted accordingly to maintain a suggested level of 5-15 ng/mL. Tacrolimus taper can be initiated at a minimum of 90 days post HCT if there is no evidence of active GVHD. The rate of tapering will be done according to institutional practices but patients should be off tacrolimus by Day 180 post HCT if there is no evidence of active GVHD
    Other Names:
  • Prograf®
  • FK506
  • Drug: Mycophenolate Mofetil
    MMF will be given at a dose of 15 mg/kg/dose ter in die (TID) (based upon actual body weight) with the maximum total daily dose not to exceed 3 grams (1g TID, IV or PO). MMF prophylaxis will start Day +5 and discontinue after the last dose on Day +35, or may be continued if active GVHD is present.
    Other Names:
  • CellCept®
  • MMF
  • Drug: Cyclophosphamide
    Cyclophosphamide [50 mg/kg ideal body weight (IBW); if actual body weight (ABW) < IBW, use ABW] will be given on Day +3 (between 60 and 72 hours after the start of the PBSC infusion) and on Day +4 post-transplant (approximately 24 hours after Day +3 cyclophosphamide). Cyclophosphamide will be given as an IV infusion over 1-2 hours (depending on volume).
    Other Names:
  • Cytoxan®
  • Outcome Measures

    Primary Outcome Measures

    1. GVHD-free, Relapse-free survival (GRFS) probability [1 year]

      The primary endpoint is GRFS as a time to event endpoint from the time of randomization. All transplanted patients will be followed for the primary endpoint for one year; however the primary endpoint will be analyzed as a time to event endpoint. The primary analysis will be done using the intent-to-treat principle.

    Secondary Outcome Measures

    1. Acute GVHD [Days 100, 180, and 1 year]

      Incidence of acute GVHD grade II-IV and grade III-IV at Days 100, 180 and 1 year will be estimated with 95% confidence intervals for each treatment group - using the cumulative incidence estimate, treating death prior to aGVHD as a competing event.

    2. Chronic GVHD [1 year]

      Incidence of chronic GVHD at 1 year will be estimated with 95% confidence intervals for each treatment group using the cumulative incidence estimate, treating death prior to chronic GVHD as a competing event.

    3. Immunosuppression-free Survival [1 year]

      Proportions of patients alive, relapse free, and off immune suppression at 1 year will be described for each treatment group, along with 95% confidence intervals.

    4. Hematologic Recovery [Days 28 and 100]

      Probabilities of neutrophil recovery by Day 28 and Day 100 will be described with 95% confidence intervals for each treatment group using the cumulative incidence estimate, treating death as a competing event.

    5. Donor Cell Engraftment [Days 28 and 100]

      Donor chimerism at Day 28 and Day 100 after transplantation in each of the randomized treatment arms will be described numerically as median and range for those evaluable as well as according to proportions with full (>95% donor cell), mixed (5.0-94.9% donor cells), graft rejection (<5%), or death prior to assessment of donor chimerism.

    6. Disease Relapse or Progression [1 year]

      Incidence of disease relapse or progression at 1 year will be estimated with 95% confidence intervals for each treatment group using the cumulative incidence estimate, treating death prior to disease relapse as a competing event.

    7. Transplant-related Mortality [Days 100, 180 and 1 year]

      Incidence of transplant-related mortality (TRM) at Days 100, 180 and 1 year will be estimated for each treatment group using the cumulative incidence estimate, treating disease relapse or progression as a competing event.

    8. Toxicity grade over time [1 year]

      All Grade 3-5 toxicities will be tabulated by grade for each randomized treatment arm, by type of toxicity as well as the peak grade overall. Toxicity frequencies up to 1 year will be described for each time interval as well as cumulative over time.

    9. Infections [1 year]

      The number of infections and the number of patients experiencing infections will be tabulated for each randomized treatment arm by type of infection, severity, and time period after transplant.

    10. Disease-free Survival [1 year]

      Kaplan-Meier curves will be constructed to estimate 1 year disease free survival probabilities for each treatment group.

    11. Overall Survival [1 year]

      Kaplan-Meier curves will be constructed to estimate 1 year overall survival probabilities for each treatment group.

    12. Post-Transplant Lymphoproliferative Disease (PTLD) [1 year]

      Probabilities of PTLD at 1-year post transplant will be described with 95% confidence intervals for each treatment group using the cumulative incidence estimate, treating death as a competing event.

    13. Patient-Reported Outcomes (PRO) [Days 100, 180 and 1 year]

      Patient-Reported Outcomes will be measured at baseline then at Days 100, 180 and one year post HCT. Using a repeated measures model, we will compute PRO composite scores and compare treatments after adjustment for baseline characteristics as described for the primary endpoint.

    14. Diversity of Immune Repertoire [3, 6, 12, and 24 Months]

      To study the diversity of the immune repertoire post-transplant and correlate with clinical outcomes, as well as study the impact on immune recovery of the method of GVHD prophylaxis and other patient and transplant factors.

    15. Diversity and Composition of the Gut Microbiome [3, 6, 12, and 24 Months]

      To study the diversity and composition of the gut microbiome post-transplant and correlate with clinical outcomes, as well as study the impact on the microbiome of the method of GVHD prophylaxis and other patient and transplant factors.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    1. Age 18.0 years or older at the time of enrollment on Segment A

    2. Patients with acute leukemia or chronic myelogenous leukemia with no circulating blasts and with less than 5% blasts in the bone marrow

    3. Patients with myelodysplasia/chronic myelomonocytic leukemia with no circulating blasts and with less than 10% blasts in the bone marrow (higher blast percentage allowed in MDS due to lack of differences in outcomes with <5% vs. 5-10% blasts in this disease)

    4. Patients with relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma with chemosensitive disease at time of transplantation

    5. Patients with lymphoma [follicular lymphoma, Hodgkin lymphoma, diffuse large B cell lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma, angioimmunoblastic T-cell lymphoma and anaplastic large cell lymphoma] with chemosensitive disease at the time of transplantation

    6. Planned reduced intensity conditioning regimen (see eligible regimens in Table 2.4a)

    7. Patients must have a related or unrelated peripheral blood stem cell donor as follows:

    8. Sibling donor must be a 6/6 match for Human Leukocyte Antigen-A (HLA)-A and -B at intermediate (or higher) resolution, and -DRB1 at high resolution using DNA-based typing, and must be willing to donate peripheral blood stem cells and meet institutional criteria for donation.

    9. Unrelated donor must be a 7/8 or 8/8 match at HLA-A, -B, -C and -DRB1 at high resolution using DNA-based typing. Unrelated donor must be willing to donate peripheral blood stem cells and meet National Marrow Donor Program (NMDP) criteria for donation.

    10. Cardiac function: Left ventricular ejection fraction at least 45%

    11. Estimated creatinine clearance acceptable per institutional guidelines

    12. Pulmonary function: Diffusing capacity of lung for carbon monoxide (DLCO) corrected for hemoglobin at least 40% and forced expiratory volume at one second (FEV1) predicted at least 50%

    13. Liver function acceptable per institutional guidelines

    14. Karnofsky Performance Score at least 60%

    15. Female patients (unless postmenopausal for at least 1 year before the screening visit, or surgically sterilized), agree to practice two (2) effective methods of contraception at the same time, or agree to completely abstain from heterosexual intercourse, from the time of signing the informed consent through 12 months post-transplant (see Section 2.6.4 for definition of postmenopausal)

    16. Male patients (even if surgically sterilized), of partners of women of childbearing potential must agree to one of the following: practice effective barrier contraception (see Section 2.6.4 for list of barrier methods), or abstain from heterosexual intercourse from the time of signing the informed consent through 12 months post-transplant

    17. Plans for the use of post-transplant maintenance therapy must be disclosed upon enrollment and must be used irrespective of the outcome of the randomization. Please note that THIS DOES NOT INCLUDE INVESTIGATIONAL AGENTS and maintenance therapy with investigational treatment requires approval by the study chairs.

    18. Voluntary written consent obtained prior to the performance of any study-related procedure that is not a part of standard medical care, with the understanding that consent may be withdrawn by the patient at any time without prejudice to future medical care.

    Exclusion Criteria:
    1. Prior allogeneic transplant

    2. Active central nervous system (CNS) involvement by malignant cells

    3. Patients with secondary acute myeloid leukemia arising from myeloproliferative disease, including chronic myelomonocytic leukemia (CMML)

    4. Patients with uncontrolled bacterial, viral or fungal infections (currently taking medication and with progression or no clinical improvement) at time of enrollment.

    5. Presence of clinically significant fluid collection (ascites, pleural or pericardial effusion) that interferes with methotrexate clearance or makes methotrexate use contraindicated

    6. Patients seropositive for human immunodeficiency virus (HIV) with detectable viral load. HIV+ patients with an undetectable viral load on antiviral therapy are eligible.

    7. Myocardial infarction within 6 months prior to enrollment or New York Heart Association (NYHA) Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia.

    8. Female patients who are pregnant (as per institutional practice) or lactating

    9. Patients with a serious medical or psychiatric illness likely to interfere with participation in this clinical study

    10. Patients with prior malignancies except resected non-melanoma skin cancer or treated cervical carcinoma in situ. Cancer treated with curative intent ≥ 5 years previously will be allowed. Cancer treated with curative intent < 5 years previously must be reviewed and approved by the Protocol Officer or Chairs.

    11. Planned use of antithymocyte globulin (ATG) or alemtuzumab in conditioning regimen

    Contacts and Locations

    Locations

    SiteCityStateCountryPostal Code
    1University of Alabama at BirminghamBirminghamAlabamaUnited States35294
    2City of Hope National Medical CenterDuarteCaliforniaUnited States91010
    3University of California, San FranciscoSan FranciscoCaliforniaUnited States94143
    4Stanford Hospital and ClinicsStanfordCaliforniaUnited States94305
    5University of Florida College of Medicine (Shands)GainesvilleFloridaUnited States32610
    6University of MiamiMiamiFloridaUnited States33136
    7H. Lee Moffitt Cancer CenterTampaFloridaUnited States33624
    8Emory UniversityAtlantaGeorgiaUnited States30322
    9Blood & Marrow Transplant Program at Northside HospitalAtlantaGeorgiaUnited States30342
    10University of ChicagoChicagoIllinoisUnited States60637
    11Loyola UniversityMaywoodIllinoisUnited States60153
    12Indiana University Simon Cancer CenterIndianapolisIndianaUnited States46202
    13Indiana BMT - St. Francis HospitalIndianapolisIndianaUnited States46327
    14University of Iowa Hospitals and ClinicsIowa CityIowaUnited States52242-1009
    15University of Kansas HospitalKansas CityKansasUnited States66160
    16Johns Hopkins UniversityBaltimoreMarylandUnited States21231
    17Dana Farber Cancer Institute/Brigham & Women'sBostonMassachusettsUnited States02115
    18Dana Farber Cancer Institute/Massachusetts General HospitalBostonMassachusettsUnited States02115
    19University of MichiganAnn ArborMichiganUnited States48109
    20Karmanos Cancer Institute, Children's Hospital of MichiganDetroitMichiganUnited States48201
    21University of MinnesotaMinneapolisMinnesotaUnited States55455
    22Mayo Clinic - RochesterRochesterMinnesotaUnited States55905
    23Washington University/Barnes Jewish HospitalSaint LouisMissouriUnited States63110
    24Mount Sinai Medical CenterNew YorkNew YorkUnited States10029
    25Memorial Sloan-Kettering Cancer CenterNew YorkNew YorkUnited States10174
    26University of North CarolinaChapel HillNorth CarolinaUnited States27599
    27Duke University Medical CenterDurhamNorth CarolinaUnited States27705
    28University Hospitals of Cleveland/Case WesternClevelandOhioUnited States44106
    29Cleveland Clinic FoundationClevelandOhioUnited States44195
    30Ohio State/Arthur G. James Cancer HospitalColumbusOhioUnited States43210
    31Oregon Health & Science UniversityPortlandOregonUnited States97239-3098
    32University of Pennsylvania Cancer CenterPhiladelphiaPennsylvaniaUnited States19104
    33Medical University of South CarolinaCharlestonSouth CarolinaUnited States29425
    34Baylor College of Medicine/The Methodist HospitalHoustonTexasUnited States77030
    35University of Texas, MD Anderson Cancer Research CenterHoustonTexasUnited States77030
    36Virginia Commonwealth University, MCV HospitalRichmondVirginiaUnited States23298
    37Fred Hutchinson Cancer Research CenterSeattleWashingtonUnited States98109-1024
    38University of Wisconsin Hospital & ClinicsMadisonWisconsinUnited States53792-5156
    39Medical College of WisconsinMilwaukeeWisconsinUnited States53211

    Sponsors and Collaborators

    • Medical College of Wisconsin
    • National Heart, Lung, and Blood Institute (NHLBI)
    • Blood and Marrow Transplant Clinical Trials Network
    • National Cancer Institute (NCI)
    • National Marrow Donor Program

    Investigators

    • Study Director: Mary Horowitz, MD, MS, Center for International Blood and Marrow Transplant Research

    Study Documents (Full-Text)

    More Information

    Additional Information:

    Publications

    None provided.
    Responsible Party:
    Medical College of Wisconsin
    ClinicalTrials.gov Identifier:
    NCT03959241
    Other Study ID Numbers:
    • BMT CTN 1703/1801
    • 2U10HL069294-11
    First Posted:
    May 22, 2019
    Last Update Posted:
    Nov 1, 2021
    Last Verified:
    Oct 1, 2021
    Individual Participant Data (IPD) Sharing Statement:
    Yes
    Plan to Share IPD:
    Yes
    Studies a U.S. FDA-regulated Drug Product:
    Yes
    Studies a U.S. FDA-regulated Device Product:
    No
    Product Manufactured in and Exported from the U.S.:
    No
    Keywords provided by Medical College of Wisconsin
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Nov 1, 2021